莱伯泰科(688056) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥86,637,366.07, representing a year-on-year increase of 0.32%[5] - The net profit attributable to shareholders for the same period was ¥19,230,814.23, reflecting a significant increase of 15.14% compared to the previous year[5] - The net profit after deducting non-recurring gains and losses reached ¥16,832,213.44, with a year-on-year growth of 2.13%[5] - Total operating revenue for the first three quarters of 2021 reached ¥268,790,694.92, an increase of 19.4% compared to ¥225,128,398.73 in the same period of 2020[22] - The total profit for Q3 2021 was CNY 63,858,580.60, an increase from CNY 42,921,626.68 in Q3 2020, representing a growth of approximately 48.8%[25] - The net profit for Q3 2021 reached CNY 53,574,188.46, compared to CNY 36,286,894.32 in the same period last year, marking a year-over-year increase of about 47.9%[25] - Basic and diluted earnings per share for Q3 2021 were both CNY 0.80, up from CNY 0.70 in Q3 2020, reflecting a 14.3% increase[26] Research and Development - Research and development expenses totaled ¥8,806,554.63, which is an increase of 35.42% year-on-year, accounting for 10.16% of operating revenue[6] - The company plans to continue increasing its R&D investment to enhance product development and market competitiveness[11] - Research and development expenses for the first three quarters of 2021 were ¥22,912,658.79, up from ¥18,965,700.13 in 2020, an increase of 20.4%[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥857,416,512.13, showing a slight increase of 0.59% from the end of the previous year[6] - Cash and cash equivalents as of September 30, 2021, were ¥507,795,593.35, down from ¥616,546,148.93 at the end of 2020, a decrease of 17.6%[18] - Total assets as of September 30, 2021, amounted to ¥857,416,512.13, slightly up from ¥852,373,343.14 at the end of 2020[20] - Total liabilities decreased to ¥81,879,861.45 from ¥111,452,422.06 at the end of 2020, a reduction of 26.5%[20] - The company's total equity as of September 30, 2021, was ¥775,536,650.68, compared to ¥740,920,921.08 at the end of 2020, an increase of 4.7%[20] Cash Flow - The cash flow from operating activities for the year-to-date was ¥11,902,191.39, reflecting a decrease of 72.21%[6] - Cash flow from operating activities for the first nine months of 2021 was CNY 289,239,138.00, compared to CNY 272,368,049.30 in the same period of 2020, indicating a growth of approximately 6.2%[29] - The company reported a net cash decrease of CNY 63,632,627.86 in Q3 2021, contrasting with a net increase of CNY 372,511,437.53 in Q3 2020[31] Shareholder Information - Total number of common shareholders at the end of the reporting period is 3,199[14] - The largest shareholder, Beijing LabTech Management Consulting Co., Ltd., holds 24,177,000 shares, representing 36.09% of total shares[14] - LabTech Holdings, Inc. is the second largest shareholder with 16,118,000 shares, accounting for 24.06%[14] - The top ten shareholders include various investment funds, with the largest being WI HARPER FUND VII holding 3,705,000 shares (5.53%)[15] - The company has no pledged, marked, or frozen shares among its top shareholders[14] Subsidiary and Investments - The company established a wholly-owned subsidiary, Shanghai LabTech Industrial Co., Ltd., with a registered capital of RMB 10 million on September 24, 2021[17] - The new subsidiary will focus on the production and sale of medical devices and related technical services[17] - The company plans to use raised funds to invest in the new subsidiary and expand its operational capabilities[17] - The report indicates a focus on expanding market presence through new product development and strategic investments[17] - The company received government subsidies amounting to ¥3,000,000 during the reporting period, compared to ¥2,000,000 in the same period last year due to a patent litigation provision[11] Other Financial Metrics - The basic earnings per share for Q3 2021 was ¥0.29, a decrease of 3.33% compared to the same period last year[6] - The weighted average return on equity was 2.52%, down by 1.08 percentage points from the previous year[6] - The company reported a net credit impairment loss of ¥524,690.42 for the first three quarters of 2021, compared to a loss of ¥734,585.46 in the same period of 2020[24] - The company recorded other comprehensive income after tax of CNY -1,198,161.73 in Q3 2021, an improvement from CNY -2,740,660.81 in Q3 2020[25] - The total comprehensive income for Q3 2021 was CNY 52,376,026.73, up from CNY 33,546,233.51 in Q3 2020, representing a growth of approximately 56.0%[26]